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Intercellular adhesion molecule-I (ICAM-I) functions as a 
ligand for lymphocyte function-associated antigen-I (LFA-
1), and thereb~ plays a crucial ro.le in mediating ~ell-c~ll 
interactions m mflammatory reactlOns. Human eosll1ophlls 
represent important effector cells in allergic skin diseases. To 
gain more insigh.t into the capac~ty of.eosinophils to physi-
cally interact with LFA-l-posltlve ll1fl~mmatory. leuk?-
cytes, in th~ present st~dy ICAM-l express~on m eosmophds 
was investigated. USll1g fluorescence-activated cell sorter 
analysis, it could b.e shown that highly purifie~ (~~5%) eo-
sinophils from penpheral blood of non-atopic mdlvlduals do 
not constitutively express ICAM-l molecules. However, 
stimulation of eosinophils with interferon gamma (IFNy), 
tumor-necrosis factor alpha (TNFa), or interleukin 3 (IL-3) 
markedly upregulated ICAM-l surface expression in a time-
and dose-dependent manner. Cytokine-induced ICAM-l ex-
pression in human eosinophils was corroborated by Northern 
blot analysis. Accordingly, unstimulated eosinophils did not 
B lood and tissue eosinophilia are major features of aller-gic reactions and parasitic infestations [1 - 3]. Accord-ingly, in allergic asthma an increased number of low-density eosinophils in the blood and signs of eosinophil degranulation and mediator release into lung tissue, 
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. express significant amounts ofICAM-1 mRNA, but ICAM-
1 mRNA expression could be markedly induced in these cells 
upon stimulation with IFNy plus TNFa. The combination 
of TN Fa with either IFNy, IL-3, IL-5, or granulocyte/ma-
crophage colony-stimulating factor (GM-CSF) increased 
ICAM-l expression in a synergistic fashion, whereas IL-5 or 
~M-S=SF by itself did not induce ICAM-l expression. Cyto-
kll1e-ll1duced ICAM-l expression was specific, because IL-
ia, I.L-lp, IL-2, IL~4, IL-6, IL-7, IL-8, C5a, and platelet-ac-
tlvatmg factor did not significantly affect eosinophil 
ICAM-l surface expression. In summary, these studies indi-
cate that eosinophils may be activated to express the adhesion 
molecule ICAM-l upon stimulation with selected inflamma-
tory cytokines, which may allow adhesion-mediated cross-
talk between eosinophils and LFA-l-positive cells . In addi-
tion, these data demonstrate for the first time a role for IL-3 
IL-5, and GM-CSF in regulation of ICAM-l expression i~ 
human cells.] I,west DennatoI100:417-423, 1993 
associated with decreased lung function, could be demonstrated 
[4-7]. In addition, there is evidence for eosinophil activation in 
lesio~al ski~ in urticaria and bullous pemphigoid [8] . In atopic der-
matitis, eosillophil accumulation in the dermis after patch testing 
With aeroaller~ens has been found to be a prominent feature [9] . 
M~reover, eO~l11ophll-denved granule proteins such as eosinophil 
catIOnic JJrotelll (ECP) or major basic protein are present in lesional 
atopic skl11, and ECP serum levels were found to correlate with 
dis~ase activity in atopi.c d~rmatitis. Taken together, these studies 
llldicate an active partiCipatIOn of eosinophils in the pathogenesis of 
atopic dermatitis [8,10,11] 
Intercellular adhesio~ molecule-l (ICAM-l) plays a pivotal role 
for the development of 1l1flammatory responses [12] . ICAM-l is an 
Imm~no.globu~1l1-li~e 90-kDa transmembrane glycoprotein [13] 
that IS lughly lllduclble 111 a vanety of cells including endothelial 
cells, fibroblasts, monocytes, melanocytes, and keratinocytes upon 
appropnate Cytokllle stlll1UlatlOn [14]. The function of ICAM-l in 
immunologic processes is mainly given by its capacity to serve as a 
ligand for lymphocyte functIOn-associated antigen-l (LFA-l), and 
ICAM-l .expresslOn may be an Important prerequisite for the capac-
Ity of a given cell type to physically interact with LFA-l - positive 
cells such as cytotoxic or helper T cells, Langerhans cells, mOl1O-
~ytes, or granu.l ocyt~s [14,15] . Studies assessing ICAM- t expression 
111 huma.n eosillopiuls are controversial. Previous reports showed 
that penpheral blood eosinophils by themselves do not express 
ICAM~ 1 on their cell surface [16,17] . This is in contrast to a recent 
report 1I1dlcat1l1g that sputum eosinophils from symptomatic asth-
matics express sl.glllficant amounts of ICAM-l (18] . To clarify 
ICAM-l expressIOn \11 human eosinophils, in the present study, 
ICAM- t surface and mRN A expression in a first attempt was as-
0022-202Xj93/$06.00 Copyright © 1993 by The Society for Investigative Dermatology, Inc. 
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sessed in vitro in highly purified blood eosinophils from non-atopic 
individuals. 
MATERIALS AND METHODS 
Control subjects Non-atopic healthy blood donors (n = 5) were 
investigated. Atopy was excluded by history, skin prick tests, and 
laboratory findings. Accordingly, total immunoglobulin E (lgE) 
and specific IgE to timothy, cultivated rye, common silver birch, 
mugwort, cat, cladosporium herbarum, and dermatophagoides 
pteronissinus were determined in sera using the CAP IgE FEIA 
(Kabi-Pharmacia, Freiburg, Germany). The donors did not receive 
any medication for at least 4 weeks prior to blood collection. 
Cytokines and Reagents Escherichia coli-derived recombinant 
human (rh) tumor necrosis factor a (TNFa) and rh TNFP were 
produced by BASF, Ludwigshafen, Germany, with a specific activ-
ity of 8.5 X 106 U/mg and 6 X 107 U/mg protein for TNFa and 
TNFP, respectively [19]. Recombinant human interleukin-5 (IL-5) 
with a specific activity of 103 U / Jig was kindly provided by the 
Glaxo Institute for Molecular Biology, Geneva, Switzerland. Re-
combinant human IL-8 was a kind gift from the Sandoz Research 
Institute, Vienna, Austria. Recombinant human granulocyte/mac-
rophage colony-stimulating factor (GM-CSF) with a specific activ-
ity of5 X 107 U/mg was kindly provided by Behring-Werke, Mar-
burg, Germany. Recombinant human IL-la, IL-1P, IL-2, IL-3, 
IL-4, IL-6, and IL-7 were purchased from Genzyme, Boston, MA. 
Before testing, all cytokines were diluted in phosphate-buffered 
saline (PBS) containing 50 /1g/ml bovine serum albumin (BSA). E. 
coli - derived rh C5a and platelet-activating factor (PAF) were ob-
tained from Sigma, Munich, Germany. A stock solution of 10-2 M 
PAF was prepared in ethanol dimethylsulfoxide (DMSO) 50: 50 
lv/v] and stored at -70°C; dilutions were made in PBS containing 
1 mg/ml BSA: Phorbol-myristate acetate (PMA) and purified BSA 
were obtained from Sigma, Munich, Germany. S-form lipopoly-
saccharide (LPS) from Salmonella abortus equi was a kind gift 
FITC 
IgGl 
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from Dr. C. Galanos, MPI for Immunobiology, Freiburg, Ger-
many. 
Antibodies A mouse monoclonal antibody (MoAb) against 
CD16 (BW 209/2) was a gift from Dr. R. Kurrle, Behring-W erke, 
Marburg, Germany. Mouse IgGl MoAb against ICAM-2 (6D5) 
was kindly provided by Dr. C.A. Gahmberg, Helsinki, Finnland. 
Mouse IgGl MoAb against ICAM-l/CD54 (clone 84HI0, Balb/c 
spleen cells X myeloma MOPC 315), against LFA-l gp 170/ 
CDlla (clone 25.3.1, myeloma X 63 - Ag 8.653 X Balb/c spleen 
cells), against LFA-l p-chain/CD18 (clone BL5, SP2/0-
Ag.14 X Balb/c spleen cells) and mouse IgGl isotype control anti-
body (myeloma X 63 Ag.8 X Balb/c spleen cells) were purchased by 
Immunotech S.A., Marseille, France. Fluorescein-conjugated goat 
anti-mouse Fab2 (anti-mouse IgG) purified by immunoaffinity chro-
matography was obtained from Dianova, Hamburg, Germany. 
Isolation and Purification of Human Eosinophil Granulo-
cytes Human granulocytes were isolated from heparin-anticoa-
gulated venous blood of normal non-atopic blood donors as de-
scribed [20] by ficoll-gradient centrifugation (Kabi-Pharmacia, 
Freiburg, Germany) and three 30-second cycles of 0.2% NaCI 
treatment followed by the addition of an equal volume of 1.6% 
NaCI to lyse red blood cells. Granulocyte preparations of non-ato-
pic controls contained approximately 4.6 ± 0.4% eosinophil gran-
ulocytes as judged by Pappenheim stain of cytospin preparations. 
Cells were more than 95% viable by trypan blue exclusion. For 
further purification of eosinophils, granulocytes were resuspended 
at a concentration of 107 ml in HEPES-buffered Hanks' balanced 
salt solution, pH 7.4, containing 1 mg/ml BSA (HBSS/BSA). 
Eosinophils were purified from granulocyte preparations in a 
modification of a method described previously [21]. For this pur-
pose immunomagnetic beads (Dynabeads M-450, Dynal, Norway) 
were coated with monoclonal aCD16 antibodies. In brief, 2-ml 
beads (4 X 108 beads/ml) were mixed with 50/11 aCD16 (1 mg/ 
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Pi.gure 1. FACSanal~sis of constitutive expression of ICAM-I, ICAM-2, and LFA-I in isolated peripheral blood eosinophils. Staining of eosinophils 
With fluorescem lsothlOcya~a.te (FITC)-:Fab2 with~ut a primary antibody (left top) and staining with monoclonal lgCl isotope control antibody plus 
FITC-Fab2 (left boaom). Stammg of eosmophlls With MoAb against ICAM-I and lCAM-2 (middle) and staining of eosinophils with MoAb against 
LFA-l/a-cham as well as LFA-llfi-chain (dght) as described in Materials alld Methods. Data are given as histograms of cell number versus fluorescence 
mtenslty. Data represent one of five nearly Identical experiments. Vertica l bar, cutoff for the IgCI control. 
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m l) and incubated for 24 h/4 °C in Minisorp tubes (Nunc, Roskilde, 
Denmark) on a rotary mixer. Coated beads were washed three times 
in HBSS/BSA and the beads retrieved using a Dynal Magnetic 
Particle Concentrator MPC-6. aCD16-coated beads were stored at 
a concentration of2 X 108 beads/ml HBSS/BSA under sterile con-
ditions for a maximum of 4 weeks at 4 ° C. 
Five-hundred microliters granulocytes were centrifuged in Mini-
sorp tubes for 7 min/820 gat 4 ° C and the supernatant was aspirated; 
subsequently 250,u1 of the aCD16-coated beads were added to the 
pellet. The mixture was incubated for 1 h/ 4 ° C on a rotary mixer. 
Thereafter, HBSS/BSA was added and PMNs, which were coupled 
to the beads, were removed magnetically using the MPC-6 device. 
Supernatant was aspirated and residual beads were removed by a 
second magnetic separation step. Eosinophils in the supernatant 
were washed as described above and resuspended at a concentration 
of 106/ ml in HBSS/BSA. Eosinophils were quantitated with Ki-
mura stain [22] in a N eubauer counting chamber. If the purity of the 
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cells was less than 95%, the magnetic purification procedure was 
repeated . Cytospin preparations of the cells used in the experiments 
described below had a purity of;;:: 95% as shown by Pappenheim 
stain. 
Cell Culture For culture human eosinophils were plated in six-
well tissue-culture plates (Costar, Cambridge, MA) at a density of 
105/ml in a final volume of 2 ml cell suspension. Cells were main-
tained in RPM I 1640 supplemented with 10% fetal calf serum and 
1 % penicillin/s treptomycin (Gibco, Berlin, Germany) with or 
without cytokines as indicated. C ulture was performed under de-
fined conditions in a humidified atmosphere at 37°C containing 5% 
CO2 , At th e indicated time points, cells were collected and centri-
fuged at 820 g for 7 min at 4 ° C. Viability was more than 95%, tested 
by trypan blue exclusion. 
The human carcinoma cell line KB (American Type Culture 
Collection, Rockville, MD) was maintained with or without cyto-
costimulation with 
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Figure 2. ICAM-I surface expression in eosinophils. Eosinophils were incubated for 24 h without stimulus (first CO I Il IllIl) , stimu.lated with indicated 
cytokines (secolld colli III II) or co-stimulated either with IFNy plus indicated cytokines (third collllll1l) or TNFIl plus indicated cytokines (joll rth column). 
ICAM-I surface expression was determined by FACS analysis as described in Materials and Methods using MoAb 84HI0. Staining of unstimulated 
eosinophils with mouse IgGJ isotype control antibody (first COIIlIllIl , top). Data are given as histograms of cell number versus fluorescence intensity. 
Histograms represent one of five essentially identical experiments. Right vertical bar, cutoff for the IgGI control. Left vertical bar, peak deviation of 
ICAM-I-positive cells. 
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kine stimulation as indicated in monolayer cultures in Dulbecco's 
modified Eagle's medium (Seromed, Berlin, Germany) containing 
5% fetal calf serum in a humidified atmosphere containing 5% CO2 
as previously described [23]. Cells were grown in 140 X 20 mm 
culture petri dishes as indicated (Becton Dickinson, Mountain 
View, CA) until subconfluency (approximately 3 X 107 cells/dish). 
Flow Cytometry Surface marker expression was determined by 
flow cytometry using a FACScan (Becton and Dickinson, Mountain 
View, CA). Eosinophils (2 X 105) were incubated with the primary 
monoclonal antibody (MoAb) or the equivalent amount of a mouse 
isotype control antibody for 30 min at 4°C. Optimal staining was 
obtained with the following antibody dilutions or concentrations: 
MoAbaICAM-l/CD54 (1: 40),aLFA-l,a-chain/CD11a (1: 40), 
aLFA-l, p-chain/CD18 (1 : 40) . The aICAM-2 MoAb was used at 
a concentration of 100 ,ug/m!. Subsequently, cells were washed 
twice in PBS, containing 0.01 % sodium azide, resuspended and 
incubated with a 1: 20 dilution of goat-anti mouse fluorescein 
isothiocyanate - (F AB 2) for another 30 min at 4 ° C. Thereafter, cells 
were washed twice and analyzed immediately. Data are given either 
as histograms of fluorescence intensity versus cell number or as 
percent reactive cells in comparison to unstimulated control cells as 
previously described [23]. 
Northern Blot Analysis Northern blot analysis was performed 
as previously described [23]. Briefly, 6 h after culture, eosinophils, 
and, 4 h after culture, K.B cells were harvested and total RNA iso-
lated by extraction with an acid guanidinium thiocyanate-phenol-
chloroform mixture as described [24] . The concentration of RNA 
was determined from A260 nm, and A260/ A280 ratios were 
greater than 1.7. Ten micrograms of RNA was electrophoresed in 
1.2% agarose gels containing formaldehyde (2.2 M) followed by 
transfer to nylon membranes (Hybond N, Amersham-Buchler, 
Braunschweig; Germany). Equivalent loading and uniform RNA 
transfer were assured by ethidium bromide staining of the gels be-
fore and after northern transfer. Membranes were prehybridized 
(4 h) and hybridized (overnight) at 42 °C with 6 X SSPE/5 X 
Denhardt's solution/200 ,ug/ml salmon sperm DNA. ICAM-l -
specific mRNA was detected using a 3.0-kB cDNA, kindly pro-
vided by Dr. T.A. Springer, Boston, MA. The cDNA fragments 
were Biotin-14-dATP labeled by nick translation using the Bio-
Nick labeling system (Gibco/BRL, Berlin, Germany) [25] . North-
ern blot analysis was performed under stringent washing conditions 
(2 X 5 min using 2 X SSC/0.5% sodium dodecyl sulfate (SDS) at 
60 °C and 1 X 40 min using 0.1% SSC/l% SDS at 50 °C). Signals 
were detected using the Photogene detection system (Gibco/BRL, 
Berlin, Germany) . Autoradiography was carried out for 15 min at 
25 ° C by using Kodak XAR films. 
Statistical Analysis Statistical significance of the data was calcu-
lated using the Mann-Whitney U test. 
RESULTS 
Constitutive Expression of Adhesion Molecules ICAM-l, 
ICAM-2, and LFA-l on Human Eosinophils In initial experi-
ments, constitutive expression of the adhesion molecules ICAM-l, 
ICAM-2, and LFA-l was assessed in freshly isolated eosinophils by 
fluorescence-activated cell sorter (FACS) analysis. Eosinophils sig-
nificantly expressed the LFA-1 molecule (a-chain/COlla and p-
chain/CD18) as previously reported [17] (Fig 1). In contrast, nei-
ther ICAM-1 nor ICAM-2 molecules could be detec'ted on the cell 
surface of eosinophils. MoAb against ICAM-2 were capable of bind-
ing to positive control cells, because in the same experiment ICAM-
2 expression could be demonstrated on peripheral blood monocytes 
(data not shown) [26] . 
Upregulation of ICAM-l Sur;face Expression by Cytokine 
Stimulation ICAM-1 expression is known to be inducible by 
incubation with selected cytokines including IFNy and TNFa. 
Therefore, the ' effect of cytokine stimulation on eosinophil ICAM-
1 expression was examined in vitro. ICAM-l surface expression 
could be significantly upregulated in vitro upon a 24-h stimulation 
with rhlFNy (10-500 U /ml) or rhTNFa (1-100 U/ml). In addi-
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Figure 3. ICAM-l surface expression in eosinophils. Eosinophils were 
incubated for 24 h without stimulus (unstimulated) or with different con-
centrations oflFNy (10-500 U Iml) as indicated. ICAM-l surface expres-
sion was determined by FACS analysis as described in Materia ls and Meth-
ods using MoAb 84H10. Top (IgGl), staining of unstimulated eosinophils 
with a mouse IgGI isotype control antibody. Vertical bar, cutoff for the IgGI 
control. 
tion, IL-3 (1-100 U /ml) was found to induce eosinophil ICAM-l 
expression (Fig 2). Cytokine-induced upregulation ofICAM-l oc-
curred in a time- and dose-dependent manner with rhIFNy being 
the most potent stimulus. Time dependence was similar for these 
cytokines showing maximal ICAM-l expression after 24 h stimula-
tion; representative data were shown for IFNy (Figs 3 and 4) . The 
combination of IF Ny with TNFa was found to induce eosinophil 
ICAM-l expression in a synergistic fashion. In contrast, no signifi-
cant effect on ICAM-l surface expression could be observed after 
incubation with r11IL-la (1-100 U /ml), rhIL-1p (1-100 U /ml), 
rhIL-2 (1-100 U/ml), rhIL-4 (1-100 Ujml), rhIL-6 (1-100 U/ 
ml), rhIL-7 (10-500 ng/ml), rhIL-8 (O.Ol-l,ug/ml), or the stim-
uli PAF (10-6 -10-8 M), C5a (10- 6 -10-8 M) and LPS (0.01-0.5 
,ug/ml), which were tested for different time points (data not 
shown). Expression ofICAM-2 on cytokine-stimulated eosinophils 
was not determined in the present study. 
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IFNy 24h 
fluorescence intensity 
Figure 4. ICAM-1 surface expression in eosinophils. Eosinophils, either 
unstimulated or stimulated with IFNy (500 U/mI), were incubated for 
different time in tervals (6 - 24 h) as indica ted. I CAM -1 surface expression 
was determined by FACS analysis as described in Materials alld Methods 
using MoAb 84H10. Top (IgGl), staining of unstimulated eosinophils with 
a mouse IgGI isotype control antibody. Vertical bar, cutoff for the IgGI 
control. 
cytokines Induce ICAM-1-Specific mRNA Cytokine-in-
duced eosinophil ICAM-l expression was confirmed by Northern 
blot analysis using a 3.0-kB eDNA specifically encoding for ICAM-
1. As shown in Fig 5, unstimulated cell s did not express ICAM-l 
mRNA. In contrast, ICAM-l mRNA expression could be signifi-
cantly upregulated after 6 h stimulation with rhIFNy (500 U jml) 
plus rhTNFa (100 Ujml). 
In addition, Northern blot analysis was performed in KB cells. 
Accordingly, low amounts of ICAM-l-specific mRNA could be 
detected in unstimulated KB cells. In contrast, ICAM-l mRNA 
expression could be significantly upregulated after 4 h stimulation 
with rhIFNy (500 Ujml) plus rhTNFa (100 Ujml). 
The observed differences in ICAM-1 mRNA expression in eosin-
ophils or KB ce lls were not due to the variations in the amounts of 
total mRN A, because there was a similar staining pattern of the gels, 
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with ethidium bromide or fJ-actin gene was found to be equally 
expressed for all lanes (data not shown). 
Co-stimulatory Effects ofCytokines on Eosinophil ICAM-1 
surface expression To investigate co-stimulatory effects of cy-
tokines, eosinophils were cultured in the presence of several cyto-
kine combinations. As is shown in Fig 2, a synergistic ICAM-1 
upregulation could be observed after the treatment of TNFa-
stimulated eosinophils with IFNy, IL-3, IL-5, or GM-CSF. The 
latter two cytokines by themselves did not exert any significant 
effect on ICAM-l surface expression. Co-stimulation of IFNy-
. treated eosinophils with IL-5 or GM-CSF did not increase ICAM-l 
surface expression above levels obtained after stimulation with 
IFNy alone (Fig 2). 
DISCUSSION 
The present study demonstrates that expression of the cell adhesion 
molecule ICAM-l may be induced in normal human eosinophils 
upon in vitro cytokine stimulation. Controversial results concerning 
ICAM-l surface expression in human eosinophils have been pub-
lished. Previous studies showed that ICAM-l is not expressed in 
peripheral blood eosinophils [1 6,17]. The present report confirms 
that ICAM-l, in contrast to its ligand LFA-1, is not expressed con-
stitutively in normal human eosinophils. In addition, ICAM-2, 
which is a newly recognized membrane protein closely related to 
the two most N-terminal domains ofICAM-l and which functions 
as a second ligand for LFA-l, is also absent from the eosinophil 
surface [27]. In contrast, it could be shown recently that sputum 
eosinophils from asthmatic patients express ICAM-l on their cell 
surface [18]. The present observation, that eosinophil ICAM-l ex-
pression is inducible by cytokines, strongly indicates that eosinophil 
ICAM-1 expression in sputum eosinophils from asthmatics is due to 
increased levels of ICAM-l inducing cytokines in these patients. 
Accordingly, sera of asthmatics were found to contain increased 
amounts of IFNy [28]. 
The present data identify the cytokines IFNy and TNFa as potent 
mediators upregulating ICAM-l surface expression in human eo-
EOS KB 
1 2 3 4 
< -- 28s 
< -- 18s 
Figure 5. ICAM-l mRNA expression in cytokine-stimulated cultured 
human eosinophils and KB cells. Northern blot analysis of total cellular 
RNA (10 I1g) using a Biotin-labeled eDNA probe encoding for lCAM-l. 
Eosinophils (EOS) were incubated for 6 h without stimulus (lalle 1) or 
stimulated with IFNy (500 U Iml) plus TNFa (100 U/ml) '(lalle 2). KB cells 
(KB) were incubated for 4 h without stimulus (latle 3) or stimulated with 
IFNy (500 U Iml) plus TNFa (100 U 1m I) (latle 4). Representative Northern 
blots of three experiments, respectively, are shown. 
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sinophils in vitro. Moreover, stimulation of eosinophils by IFNy plus 
TNFa led to an increase of ICAM-l-specific steady-state mRNA 
levels, as has been previously also shown for KB cells [23]. Inter-
feron y has been shown to induce ICAM-l surface expression in 
several other cell types including dermal fibroblasts [13J, endothe-
lial cells [29], melanocytes [30], monocytes [31]' and keratinocytes 
[32]. In addition, TNFa significantly up-regulates ICAM-l surface 
expression in vitro in endothelial cells [29], melanocytes [30] , and 
keratinocytes [32]. Moreover, the combination of TN Fa and IFNy 
was found to upregulate ICAM-1 surface expression in human eo-
sinophils in a synergistic fashion, and a similar synergistic effect 
could be previously demonstrated for keratinocytes [32]. 
The present study provides evidence that IL-3 may represent 
another cytokine capable of inducing ICAM-l expression in human 
eosinophils. Moreover, synergistic ICAM-1 induction could be ob-
served upon stimulation of eosinophils with a combination of 
TNFa plus IL-3, IL-5, or GM-CSF. These data further support the 
concept that IL-3, IL-5, and GM-CSF are potent activators and 
modulators of eosinophil functions, as was previously shown by 
their capacity to induce cytotoxicity, mediator release, and oxyda-
tive metabolism [33 - 36]. 
The mechanisms responsible for synergistic ICAM-l induction 
achieved by cytokine stimulation is unclear. For IFNy and TNFa it 
has been proposed that IFNy may induce TNF receptors [37,38] . 
However, IFNy recently was found to have no influence on TNF-
receptor surface expression in keratinocytes, although a synergistic 
induction of ICAM-1 expression by IFNy plus TNFa stimulation 
could be observed in this cell type [39] . Further studies are currently 
underway to determine the effect of cytokines on TNF-receptor 
expression in human eosinophils. Receptors for the eosinophil-acti-
vating cytokines IL-3, IL-5, and GM-CSF share a commonp-chain 
[40,41] . Therefore, it is tempting to speculate, that the observed 
synergistic effects of TNFa with these cytokines on eosinophil 
ICAM-l expression may be due to TNFa-modulated signal-trans-
duction through the common p-subunit of this cytokine receptor 
family . 
Eosinophils are believed to be important effector cells in several 
skin diseases, because a series of mediators released by eosinophils 
carabl e to induce tissue damage could be detected in lesional skin 
[8 . However, the mechanisms involved in the generation and main-
tenance of an eosinophilic infiltrate are only purely understood. The 
present study provides clear evidence that cytokine-stimulated eo-
sinophils are capable to express the adhesion molecule ICAM-l, and 
this may allow ICAM-1- positive eosinophils to physically interact 
with LFA-l -positive inflammatory cells such as lymphocytes, 
monocytes, Langerhans cells, or granulocytes. Further studies will 
determine the in vivo relevance of cytokine-induced eosinophil 
ICAM-l expression in inflammatory skin diseases, such as atopic 
dermatitis, urticaria, or bullous pemphigoid. 
We UJould like to thmlk I1diko Borsos, Christine Scholz, and Tanja WifllitlgJor 
excellent technical assistance. 
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